Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced it has entered…
Read More...
Read More...
